Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 116.52% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.24% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -29.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.08% |
| Dec 31, 2025 | -44.31% |
| Sep 30, 2025 | 93.36% |
| Jun 30, 2025 | 47.55% |
| Mar 31, 2025 | 251.34% |
| Dec 31, 2024 | 171.66% |
| Sep 30, 2024 | 289.69% |
| Jun 30, 2024 | -324.44% |
| Mar 31, 2024 | -26.07% |
| Dec 31, 2023 | 121.04% |
| Sep 30, 2023 | 128.44% |
| Jun 30, 2023 | 41.92% |
| Mar 31, 2023 | 43.17% |
| Dec 31, 2022 | -108.67% |
| Sep 30, 2022 | -71.38% |
| Jun 30, 2022 | 20.63% |
| Mar 31, 2022 | -26.32% |
| Dec 31, 2021 | -26.30% |
| Sep 30, 2021 | 21.02% |
| Jun 30, 2021 | -41.03% |